Amneal, Adalvo win FDA review acceptance for generic tirzepatide autoinjector ANDAs

Amneal, partner Adalvo won FDA acceptance for review of two ANDAs for generic tirzepatide autoinjector pens referencing Mounjaro, Zepbound. * Filings seek approval for single-dose prefilled pens across current indications, including type 2 diabetes, chronic weight management. * Amneal will lead US commercialization if cleared; IQVIA data cited U.S. tirzepatide sales rising to USD 72.8 billion in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Amneal Pharmaceuticals and partner Adalvo have received FDA acceptance for the review of two Abbreviated New Drug Applications (ANDAs) for generic tirzepatide autoinjector pens. These filings reference Mounjaro and Zepbound, seeking approval for single-dose prefilled pens for indications including type 2 diabetes and chronic weight management. Amneal will lead US commercialization if approved, with IQVIA projecting US tirzepatide sales to reach $72.8 billion by 2026.

Amneal, partner Adalvo won FDA acceptance for review of two ANDAs for generic tirzepatide autoinjector pens referencing Mounjaro, Zepbound. * Filings seek approval for single-dose prefilled pens across current indications, including type 2 diabetes, chronic weight management. * Amneal will lead US commercialization if cleared; IQVIA data cited U.S. tirzepatide sales rising to USD 72.8 billion in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here